转自：福建省药品监督管理局网站 2026年2月14日 福建省药品监督管理局GMP符合性检查结果公告（2026年第6号） 根据《药品管理法》、《药品生产监督管理办法》有关规定，经现场检查并综合评定，现将厦门伯马药业有限公司《药品生产质量管理规范》 符合性检查结果公告。 | 企业名称 | 检查地址 | 检查范围 | 检查时间 | 检 类 查 | | --- | --- | --- | --- | --- | | | | | | 型 结 | | | | | | 果 | | | 1. 持有人检查地址：厦门市 | 1.检查范围：盐酸莫西沙星氯化钠注射液（250ml：盐酸莫 | 1.持有人检查时 | 符 | | | 海沧区海沧大道567号厦门中 | 西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g，批准文 | 间：2025年12月25 | | | 厦门伯马药业有限公司 | 心E座913单元 | 号：国药准字H20243011） | 日-12月26日 | 依 | | （受托方：广东大翔制 | | | | 申 | | 药有限公司） | 2.延伸检查地址：广州市增 | 2.生产类型：委托生产 | 2.延伸检查时间： ...

American Express Co., Deere & Co. and Johnson & Johnson have dropped diversity criteria for selecting new board directors, according to a conservative shareholder activist group.Goldman Sachs Group Inc. is considering a similar change, Bloomberg confirmed earlier this week. The moves are the latest ways that pressure from conservatives is changing corporate management and governance. American Express signed an agreement in October with the nonprofit National Legal and Policy Center, an activist shareholder ...

Core Viewpoint - Novo Nordisk is a leader in the GLP-1 drug market, but its stock has underperformed recently, and achieving significant returns over the next decade may be unrealistic due to competitive pressures and market dynamics [1][4][5]. Group 1: Market Position and Products - Novo Nordisk's semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is among the top-selling GLP-1 therapies, positioning the company well for future growth [3]. - The company has a robust pipeline with several candidates expected to receive approval soon, which could enhance its market position [3][7]. Group 2: Competitive Landscape - Novo Nordisk is losing market share to Eli Lilly, its main competitor, particularly with the performance of its next-generation weight loss drug, CagriSema, which did not outperform Eli Lilly's Zepbound in clinical trials [5][7]. - Increased competition is likely to reduce clinical differentiation and pricing power for Novo Nordisk, limiting its potential upside in the market [7]. Group 3: Financial Outlook - Analysts suggest that even with optimal execution, achieving a compound annual growth rate of 25.89% to turn $100,000 into $1 million is highly unlikely for Novo Nordisk [4]. - The company's revenue is projected to decline year-over-year in 2026, indicating potential challenges ahead [5]. Group 4: Investment Considerations - Despite current struggles, Novo Nordisk's long-standing leadership in the diabetes market and its deep pipeline may present investment opportunities for long-term holders [8][9]. - The company's dividend yield of 4.47% could provide additional returns for investors willing to hold the stock over the next decade [7][9].

Core Insights - The company formerly known as Cybin has transitioned to HELUS Pharma at the beginning of January this year, indicating a rebranding and potential strategic shift in focus [1] Company Overview - HELUS Pharma is positioned in the biotechnology sector, focusing on innovative drug development through unique mechanisms of action and first-in-class therapies [1] - The company aims to reshape treatment paradigms with platform technologies that have significant market potential [1] Analyst's Approach - The analysis emphasizes a combination of scientific expertise and financial market analysis to evaluate drug candidates, competitive landscapes, clinical trial designs, and market opportunities [1] - The goal is to provide insights that help investors understand both the opportunities and risks inherent in the biotechnology sector, which is characterized by the potential for high returns through breakthrough science [1]

Core Insights - Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, marking a 21.5% year-over-year increase and exceeding the Zacks Consensus Estimate by 7.57% [1] - The company's EPS for the same quarter was $0.92, a significant increase from $0.75 a year ago, resulting in an EPS surprise of 228.57% compared to the consensus estimate of $0.28 [1] Revenue Performance - Trokendi XR generated $8.4 million in net product sales, below the average estimate of $5.81 million, reflecting a year-over-year decline of 43.2% [4] - Oxtellar XR reported $6.8 million in net product sales, surpassing the average estimate of $5.75 million, but showing a year-over-year decrease of 48.5% [4] - APOKYN achieved $9.6 million in net product sales, slightly below the average estimate of $9.93 million, with a year-over-year decline of 52.2% [4] - Qelbree's net product sales were $81 million, below the average estimate of $87.72 million, but showing an 8.9% year-over-year increase [4] - Collaboration revenue from ZURZUVAE was $32.8 million, exceeding the average estimate of $28.05 million [4] - Total net product sales amounted to $158.1 million, below the average estimate of $193.42 million, representing a year-over-year decline of 5% [4] - Royalty, licensing, and other revenues reached $20.7 million, significantly above the average estimate of $3.25 million, with a year-over-year increase of 166.6% [4] - ONAPGO net product sales were $8.9 million, exceeding the average estimate of $6.1 million [4] - GOCOVRI generated $38.6 million in net product sales, slightly below the average estimate of $42.64 million, with a year-over-year increase of 4.6% [4] Stock Performance - Supernus shares have returned +3.1% over the past month, contrasting with a -1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

智通财经APP获悉，信达证券发布研报称，首次覆盖，给予康哲药业(00867)"买入"评级，该行预计 2025-2027年公司营业收入分别为82.16亿元、98.59亿元、120.28亿元，同比增速分别为10%、20%、 22%;归母净利润分别为16.15亿元、18.50亿元、22.38亿元，同比增速分别为0%、15%、21%。该行看好 公司中长期成长性。 信达证券主要观点如下： 国内商业化能力卓越，海外东南亚市场研产销布局完备 公司具备卓越的、覆盖全链路的商业化能力，拥有约4700人的专业学术推广团队，网络深度覆盖中国超 5万家医院及医疗机构、约30万家零售药店及主流电商平台，能够高效驱动产品放量。国际化战略方 面，公司前瞻性地在东南亚市场构建了完整的研发+注册与商业化+生产一体化布局，为公司打开了长 期、可持续的第二增长曲线。 公司通过合作开发及自主研发，高效布局了近40款创新管线，并已进入成果密集兑现阶段。目前已有6 款创新药成功上市实现商业化，处于NDA阶段的重磅创新产品包括：1)注射用Y-3，用于急性缺血性脑 卒中治疗，兼具预防卒中后抑郁焦虑，2025年12月NDA受理;2)德昔度司他片，用于非透析的 ...

For the quarter ended December 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2 billion, up 10.1% over the same period last year. EPS came in at $6.64, compared to $6.60 in the year-ago quarter.The reported revenue represents a surprise of +1.56% over the Zacks Consensus Estimate of $1.18 billion. With the consensus EPS estimate being $6.62, the EPS surprise was +0.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab during the specified class period [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][7]. - The complaint alleges that Ultragenyx made false statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with clinical trial results [4][7]. - Investors have until April 6, 2026, to file for lead plaintiff status in the lawsuit [2][9]. Group 2: Stock Performance - On December 29, 2025, Ultragenyx's stock price dropped over 42%, falling from $34.19 per share to $19.72 per share after the company announced that its Phase III studies did not achieve statistical significance [5][7]. Group 3: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to discuss their legal rights [3][10]. - Options for investors include filing to be a lead plaintiff by the deadline or choosing to remain an absent class member [9].

Unlocking Biosimilar Potential Ophthalmology Case Study FEBRUARY 2026 Introduction Ensuring that challenges to biosimilar uptake are continuously assessed and addressed is a critical part of unlocking their benefits. Biosimilar use is growing across therapy areas with different specialties gaining experience and confidence. These biosimilars have also provided substantial savings for the overall health system. Between 2023 and 2025, IQVIA Institute has published two reports highlighting the importance of ph ...

ARCALYST revenue growth of 62% for full-year 2025 was primarily driven by the expanding adoption of IL-1 alpha and beta inhibition as a second-line treatment immediately following NSAID and colchicine failure. Management attributes commercial success to a fundamental shift in the treatment paradigm, supported by the 2025 ACC clinical guidance which ratified IL-1 inhibition as a preferred second-line approach. The company is leveraging its profitable ARCALYST franchise to fund strategic investments in ...